US Bancorp’s Black Diamond Therapeutics BDTX Stock Holding History

US Bancorp’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,000	Closed	-$2.43K	–	4176
2025 Q4	$2.43K	Buy	+1,000	New	+$3.54K	﹤0.01%	3722
2023 Q4	–	Sell	-700	Closed	-$2.01K	–	3987
2023 Q3	$2.01K	Hold	700	–	–	﹤0.01%	3657
2023 Q2	$3.54K	Hold	700	–	–	﹤0.01%	3568
2023 Q1	$1.32K	Hold	700	–	–	﹤0.01%	3833
2022 Q4	$1.26K	Hold	700	–	–	﹤0.01%	3886
2022 Q3	$1K	Hold	700	–	–	﹤0.01%	3917
2022 Q2	$2K	Hold	700	–	–	﹤0.01%	3795
2022 Q1	$2K	Hold	700	–	–	﹤0.01%	3802
2021 Q4	$4K	Sell	700 -379	-35%	-$2.65K	﹤0.01%	3694
2021 Q3	$9K	Buy	1,079 +379	+54%	+$3.74K	﹤0.01%	3462
2021 Q2	$9K	Hold	700	–	–	﹤0.01%	3424
2021 Q1	$17K	Hold	700	–	–	﹤0.01%	3087
2020 Q4	$22K	Hold	700	–	–	﹤0.01%	2866
2020 Q3	$21K	Buy	700 +300	+75%	+$9.13K	﹤0.01%	2789
2020 Q2	$17K	Buy	+400	New	+$14.7K	﹤0.01%	2883

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

US Bancorp's BDTX Position: Q1 2026 in Review

US Bancorp sold out of Black Diamond Therapeutics (BDTX) in Q1 2026, closing a stake of 1,000 shares — an estimated $2.43K sold.

US Bancorp first reported a position in BDTX in Q2 2020 and held it in 15 quarters. The position peaked at $22K in Q4 2020. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

US Bancorp reported no remaining Black Diamond Therapeutics position as of Q1 2026 after selling out during the quarter.
US Bancorp sold 1,000 Black Diamond Therapeutics shares in Q1 2026, an estimated $2.43K.
US Bancorp first reported a position in Black Diamond Therapeutics in Q2 2020 and held it in 15 quarters.
US Bancorp's Black Diamond Therapeutics position peaked at $22K in Q4 2020.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.